Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy

Name: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy
Start: 2027-10-05

October 5, 2027

Company: Hepion Pharmaceuticals, Inc. (CTRVP)
Drug: transthyretin
Indication: Transthyretin Amyloid Cardiomyopathy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy — CTRVP Phase 3 Readout | BioSniper